Preparation method of biodegradable medicine composite macromolecular scaffold material

A technology of composite polymers and scaffold materials, applied in medical science, medical containers, pharmaceutical packaging, etc., can solve the problems of inconvenient fiber pore formation, decrease in polymer molecular weight, and difficulty in obtaining it, so as to prevent restenosis of blood vessels and achieve good operation anti-thrombosis effect

Inactive Publication Date: 2002-09-04
TSINGHUA UNIV +1
View PDF0 Cites 32 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Canesh R. Polylactic acid was formed into a film by spraying, and then rolled into silk, but the silk was too thick to meet the needs of implanting into the human body (ASAIO Journal, M584, 1994)
L.Fambri et al. obtained polylactic acid fibers by melt spinning, but there was a serious degradation phenomenon, which caused the molecular weight of the polymer to drop by about 2 / 3 (Polymer Vol.38 NO.1 pp79-85, 1997)
Prior to this, L.Fambri et al. obtained polylactic acid fibers by dry spinning, and the degradation phenomenon was not serious, but there was a problem of poor operability, and it was difficult to obtain long uniform filaments (Journal of materials science: materials in medicine 679-683, 5, 1994), and it is not convenient to make holes in the fiber

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0039] A preparation method of a biodegradable drug composite polymer scaffold material proposed by the present invention, the method comprises the following steps in sequence:

[0040] a. The degradable polymer polylactic acid (molecular weight is 100,000 to 300,000) and polycaprolactone (molecular weight is 100,000 to 300,000) are (100%: 0%) to (0%: 100%) by mass percentage ) into the organic solvent chloroform, configured into a solution with a mass volume concentration of 1% to 20% (g / ml), stirred, and fully dissolved;

[0041] b. Add any one of the anti-restenosis drug paclitaxel, paclitaxel derivative drug paclitaxel, aryretinoin ethyl ester, probucol, dexamethasone, sirolimus to the above solution, the molar volume concentration of the drug 0.0001 ~ 10 (mol / ml), fully stir, and let stand to remove air bubbles;

[0042]c. Pour the solution prepared above into a container, let the solution volatilize at 0-30°C to form a film, and control the thickness of the film by cont...

Embodiment 1

[0067] a. Add PLLA to the organic solution chloroform to form a solution with a mass volume concentration of 1% (g / ml), stir and fully dissolve. The molecular weight of the PLLA used is 100,000.

[0068] b. Add paclitaxel to the solution to make the drug molar volume concentration 0.0001 (mol / ml). Stir well and let stand to remove air bubbles.

[0069] c. Pour the solution into a strip mold and let the solution evaporate at 0°C to form a film. The thickness of the film is controlled by controlling the amount of casting solution, and the film thickness is 0.1mm. Filaments with a width of 0.1 mm were produced.

[0070] d. Configure the anticoagulant substance solution. An aqueous solution of carboxylated sulfated chitosan with a mass volume concentration of 0.1% (g / ml) is miscible with acetone at 1:1 (volume ratio).

[0071] e. Making the polymer filaments carry a layer of anticoagulant substances. Soak the filaments in the solution prepared in (d) for 1 hour. Take out an...

Embodiment 2

[0074] a. Add PCL to the organic solution 1,4-dioxane to form a solution with a mass volume concentration of 20% (g / ml), stir and fully dissolve. The molecular weight of PCL used is 300,000.

[0075] b. Add Docetaxel to the solution to make the drug molar volume concentration 1 (mol / ml). Stir well and let stand to remove air bubbles.

[0076] c. The solution is poured into a mold and frozen at -20°C, and then put into a freeze dryer to freeze dry. The thickness of the film was controlled by controlling the amount of casting solution, and the film thickness was 0.4 mm. Filaments with a width of 0.4 mm were produced.

[0077] d. Configure the anticoagulant substance solution. An aqueous solution of carboxylated sulfated chitosan with a mass volume concentration of 20% (g / ml) is miscible with acetone 1:1 (volume ratio).

[0078] e. Making the polymer filaments carry a layer of anticoagulant substances. Filament is put into the solution prepared in (d) and soaked for 48 hour...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

A preparation method of biodegradable medicine-compounded macromolecular scaffolding material includes the following steps: dissolving macromolecular polylactic acid, polycaprolactone and restenosis-resisting medicine in the solvent, pouring the prepared solution into a container for film-forming, making the said film into filament, dipping the said filament in the mixed solution prepared with L-lactic acid and diglycolide copolymer, solvent and restenosis-resisting medicine and drying in the air or freeze-drying, then soaking the said filament in anticoagulative solution, drying in the air, making filament wind round the mould, thermosetting and forming so as to obtain the invented product. The described solvent is chloroform, 1,4-dioxane and dimethyl sulfoxide, the restenosis-resisting medicine is taxol, taxadter, arotinoid ethylester, probucol, dectan and cilomosi, and the anticoagulative solution is prepared with carboxylated sulfurnic aid esterified chitin aqueos solution or heparin sodium aqueos solution and acetone through the process of mixing and solvation reaction.

Description

technical field [0001] The invention relates to a preparation method of a biodegradable drug composite polymer scaffold material, which belongs to the technical field of bioengineering. Background technique [0002] Transcatheter interventional therapy is one of the most commonly used treatments for vascular obstructive diseases, especially percutaneous transluminal coronary angioplasty (PTCA) is a very effective treatment for coronary obstructive diseases. The metal stent currently used clinically is a kind of foreign body to the human body, which makes people have doubts about its long-term safety. Moreover, metal stents can also cause damage to the arterial wall, causing inflammation and restenosis. [0003] Degradable polymer scaffolds have good biocompatibility, and can eventually degrade and disappear in the body, avoiding long-term effects on the human body. Polymer materials can conveniently carry sustained-release drugs through adsorption grafting and other means ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/06A61L31/14A61L33/08
Inventor 崔福斋张金山孟波肖越勇王小红刘晓敏
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap